Rationale 307: Tislelizumab (Tis) Plus Chemotherapy (Chemo) Vs Chemo Alone As First-Line (1l) Treatment For Advanced Squamous Non-Small Cell Lung Cancer (Sq Nsclc) In Patients (Pts) Who Were Smokers Vs Non-Smokers

X. Yu,J. Wang,S. Lu, J. Zhao,Y. Yu,C. Hu, G. Feng,K. Ying, W. Zhuang, J. Zhou, J. Wu,S. J. Leaw, X. Lin,J. Zhang

ANNALS OF ONCOLOGY（2021）

引用 0|浏览10

暂无评分

摘要

Primary results from the phase III RATIONALE-307 study (NCT03594747) showed efficacy and a manageable safety/tolerability profile for TIS, an anti-programmed cell death protein 1 monoclonal antibody, plus chemo, as 1L treatment for sq NSCLC. We report results based on smoking status.

查看译文

关键词

lung cancer,chemotherapy,chemotherapy,tislelizumab,first-line,non-small,non-smokers

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要